Background
During HIV-1 infection, dendritic cells (DC) facilitate dissemination of HIV-1 while trying to trigger adaptive antiviral immune responses. We examined whether increased HIV-1 capture in DC matured with lipopolysaccharide (LPS) results in more efficient antigen presentation to HIV-1-specific CD4 + and CD8 + T cells. In order to block the DC-mediated trans-infection of HIV-1 and maximize antigen loading, we also evaluated a non-infectious integrase-deficient HIV-1 isolate, the HIV NL4-3ΔIN .
Methods
Immature DC (iDC), mature DC (mDC) activated with IL-1β, TNF-α, IL-6, and PGE2 (ITIP) or LPS during viral uptake, and fully mDC matured with ITIP or with LPS for 48 h before viral loading were tested. Antigen presentation to HIV-1-specific CD4 + and CD8 + T cell clones was quantified by IFN-γ ELISPOT. DC-associated p24 Gag HIV-1 and DC-mediated HIV-1 trans-infection were also evaluated in parallel.
Results
We showed that higher viral capture of DC did not guarantee better antigen presentation or T-cell activation. Greater HIV NL4-3 uptake by fully LPS-matured DC resulted in higher viral transmission to target cells but poorer stimulation of HIV-1-specific CD4 + and CD8 + T cells. Conversely, maturation of DC with LPS during-but not before-viral loading enhanced both HLA-I and HLA-II HIV-1-derived antigen presentation. On the other hand, DC maturation with ITIP during viral uptake only stimulated HIV-1-specific CD8 + T cells. Integrasedeficient HIV NL4-3ΔIN was also efficiently captured and presented by DC through HLA-I and HLA-II pathways, but in absence of viral dissemination.
Conclusion
Hence, DC maturation state, activation stimulus, and time lag between DC maturation and antigen loading impact HIV-1 capture and virus antigen presentation. Our results demonstrate a dissociation between the capacity to capture HIV-1 and to present viral antigens. HIV NL4-3ΔIN seems to be an attractive candidate to be explored. These results provide new insights into DC biology and have implications in the optimization of DC-based immunotherapy against HIV-1 infection.
